Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus

Coronary Artery Disease

Volumn 17, Issue 1, 2006, Pages 57-61

  Schneider, David J ^a   Keating, Friederike K ^a   Baumann, Patricia Q ^a   Whitaker, Deborah A ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Diabetes mellitus; Glycoprotein IIb IIIa; Kinetics; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; EPTIFIBATIDE; FIBRINOGEN; FLUOROCHROME; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; TYROSINE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MAXIMUM ALLOWABLE CONCENTRATION; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; IN VITRO STUDY; METABOLISM; THROMBOCYTE ACTIVATION;

AGED; DIABETES MELLITUS; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TYROSINE;

EID: 33646989118     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200602000-00010     Document Type: Article

References (20)

1. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64:1393-1401.
2. Peerschke EI. The platelet fibrinogen receptor. Semin Hematol 1985; 22:241-259.
3. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92:2373-2380.
4. Cook JJ, Bednar B, Lynch JJ, Gould RJ, Egbertson MS, Halczenko W, et al. Tirofiban (Aggrastat™). Cardiovasc Drug Rev 1999; 17:199-224.
5. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80:11B-20B.
6. Schneider DJ, Whitaker DA, Baumann PQ, Sobel BE. Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen. J Cardiovasc Pharm 2005; 46:41-45.
7. Huber W, Hurst J, Schlatter D, Barner R, Hubscher J, Kouns WC, Steiner B. Determination of kinetic constants for the interaction between the platelet glycoprotein IIb-IIIa and fibrinogen by means of surface plasmon resonance. Eur J Biochem 1995; 227:647-656.
8. Keating FK, Whitaker DA, Sobel BE, Schneider DJ. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes. Thromb Res 2004; 113:27-34.
9. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88:1-14.
10. Holmes MB, Sobel BE, Howard DB, Schneider DJ. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999; 95:75-82.
11. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104:181-186.
12. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91:334-336.
13. Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost 2001; 85:309-313.
14. Xia V, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labeled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol 1996; 93:204-214.
15. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F,Wan Y, Aggarwal A, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002; 90:1421-1423.
16. Gilchrist IC, O'Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001; 104:406-411.
17. Matthews JC. Fundamentals of receptor, enzyme, and transport kinetics. Florida: CRC Press Inc.; 1993.
18. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497.
19. Theroux P, Alexander J Jr, Pharand C, Barr E, Snapinn S, Ghannam AF, Sax FL. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study. Circulation 2000; 102:2466-2472.
20. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436-443.